Clinical trial NCT00047203: Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
Official title: A Phase II Study of Flavopiridol in Patients With Relapsed and Refractory Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2003-01-27
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of flavopiridol in treating patients who have relapsed or refractory multiple myeloma

Detailed description: PRIMARY OBJECTIVES:

I. Determine the response rate in patients with relapsed or refractory multiple myeloma treated with flavopiridol.

II. Determine the disease-free survival and overall survival of patients treated with this drug.

III. Correlate disease response with t(11;14)(q13;q32) rearrangement, p16 methylation status, and BCRP expression in patients treated with this drug.

IV. Correlate disease response and drug treatment with cell cycle status and effects on apoptosis and apoptosis regulatory proteins in these patients.

OUTLINE: This is a multicenter study.

Patients receive flavopiridol IV over 1 hour on days 1-3. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients achieving at least a partial response may continue treatment in the absence of disease progression or unacceptable toxicity.

Patients are followed every 6 months for 1 year.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of relapsed or refractory multiple myeloma (MM) requiring treatment

  * Durie-Salmon stage I or greater at diagnosis

    * Patients with non-secretory or oligo-secretory MM (defined as maximum urinary M-spike less than 200 mg/24 hours and a maximum serum M-spike less than 0.5 g/dL during entire disease course) must have at least 30% bone marrow plasma cells
    * Patients with secretory MM must have measurable disease defined as serum monoclonal protein of at least 1 g/dL or urinary M-spike of at least 200 mg/24 hours
* Must have received at least 1, but no more than 5 prior therapy regimens

  * Patients who have had 4 or 5 regimens are allowed provided corticosteroids and/or thalidomide are part of the regimens
  * No more than 5 prior chemotherapy regimens (as long as 2 contained dexamethasone or thalidomide)
  * Prior autologous peripheral blood stem cell transplantation is considered 1 prior regimen
* Performance status - ECOG 0-2
* Performance status - ECOG 0-3 if secondary to neuropathy or acute bone event (e.g., vertebral compression or rib fracture)
* Absolute neutrophil count at least 750/mm\^3
* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* Alkaline phosphatase no greater than 2.5 times ULN
* AST no greater than 2.5 times ULN
* Creatinine no greater than 3 mg/dL
* No myocardial infarction within the past 6 months
* Peripheral neuropathy secondary to prior drug therapy or myeloma-associated neuropathy allowed
* No other uncontrolled serious medical condition
* No uncontrolled infection
* No other active malignancy
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* See Disease Characteristics
* No prior allogeneic stem cell transplantation
* At least 10 days since prior thalidomide
* No concurrent biologic therapy
* See Disease Characteristics
* At least 2 weeks since prior myelosuppressive chemotherapy
* No other concurrent chemotherapy
* See Disease Characteristics
* No concurrent corticosteroids (including as antiemetics) except chronic corticosteroids for disorders other than myeloma (e.g., rheumatoid arthritis or adrenal insufficiency)

  * Maximum dose allowed for prednisone is no more than 10 mg/day or hydrocortisone no more than 40 mg/day
* At least 10 days since prior bortezomib or tipifarnib
* Concurrent bisphosphonates allowed if on stable dose before study entry

Primary outcomes:
measure: Confirmed response (CR, VGPR, or PR) defined as a patient who has achieved response and maintained it on two consecutive evaluations at least 4 weeks apart.
timeFrame: First 3 months of treatment
Secondary outcomes:
measure: Overall survival time
timeFrame: Time from registration to death due to any cause, assessed up to 1 year
measure: Time to disease progression
timeFrame: Time from registration to documentation of disease progression, assessed up to 1 year
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Angela Dispenzieri
role: PRINCIPAL_INVESTIGATOR
References: